François-Georges R.
- Country
- France
- Department
- Radiotherapy
Research Overview
Data & Insights
Has run more than one trial at 0 of 20 partner sites.
Specializations
Prostate Cancer & Radiotherapy
The investigator focuses on Prostate Cancer across the disease spectrum, integrating advanced Radiotherapy techniques with systemic hormonal strategies.
- Metastatic castration‑resistant prostate cancer
- High‑risk localized prostate cancer
- Intermediate‑risk prostate cancer treated with short‑course radiotherapy
- Combination of androgen deprivation therapy and novel androgen receptor inhibitors
- Biomarker‑driven neoadjuvant approaches
These efforts aim to improve disease‑free survival and PSA‑based response metrics.
Breast Cancer & Hormone Therapy
Research activities target Breast Cancer subtypes defined by estrogen receptor and HER2 status, emphasizing endocrine manipulation and targeted agents.
- ER+/HER2‑negative metastatic disease
- High‑risk early‑stage hormone‑positive disease
- Adjuvant CDK4/6 inhibition combined with endocrine therapy
- Therapeutic de‑escalation for low‑risk luminal A tumors
- Biomarker‑guided selection of PI3K pathway inhibitors
Outcomes focus on recurrence‑free intervals and long‑term tolerability.
Gastrointestinal Malignancies
The investigator’s portfolio includes major Gastrointestinal cancers such as Colon Cancer, Rectal Cancer, Pancreatic Adenocarcinoma and Ampullary Adenocarcinoma, exploring peri‑operative and metastatic strategies.
- Adjuvant FOLFOX versus capecitabine or gemcitabine
- Neoadjuvant chemoradiation with molecular response assessment
- Microsatellite‑unstable or mismatch‑repair‑deficient disease
- Combination immunotherapy with chemotherapy in metastatic settings
- Circulating tumor DNA‑guided treatment adaptation
Key metrics include disease‑free survival and pathologic response rates.
Head and Neck & Thoracic Oncology
Clinical investigations address Head and Neck Squamous Cell Carcinoma and Non‑Small Cell Lung Cancer, often in conjunction with radiotherapy and immune checkpoint blockade.
- Concurrent chemoradiation with PD‑L1 inhibition
- Adjuvant immunotherapy after surgical resection
- Management of radiation‑induced brain radionecrosis
- Targeted agents for KRAS‑mutated colorectal metastases with lung involvement
- Biomarker‑selected trials for high‑immune‑infiltrate tumors
Endpoints emphasize progression‑free survival and radiographic response.
Urothelial & Bladder Cancer
Efforts in Urothelial Carcinoma and high‑risk Bladder Cancer investigate intravesical therapies, systemic combinations, and FGFR‑targeted approaches.
- FGFR‑altered non‑muscle‑invasive bladder cancer
- Adjuvant chemotherapy versus immunotherapy in resected disease
- Combination of antibody‑drug conjugates with checkpoint inhibitors
- Neoadjuvant chemotherapy with biomarker‑driven escalation
- Evaluation of complete response after intravesical delivery systems
Research aims to reduce recurrence and improve long‑term survival.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.